ESRRA and prostate carcinoma: Importantly, our study also showed that treatments with either specific ERRα or ERG inhibitors could suppress the eNOS expressions in prostate cancer cells, suggesting that targeting the upstream regulators of eNOS could also act to suppress the eNOS-NO signaling and also implicate their potential therapeutic application in the management of advanced prostate cancer.